ZCWPW2 Inhibitors
ZCWPW2 Inhibitors encompass a variety of chemical compounds that impede the functional activity of ZCWPW2 by targeting the intricate epigenetic mechanisms that this protein is involved in. For instance, Bisindolylmaleimide I, as a specific PKC inhibitor, could attenuate the phosphorylation-dependent regulation of ZCWPW2, thereby reducing its activity in the context of histone modification. Similarly, HDAC inhibitors like Trichostatin A, Suberoylanilide Hydroxamic Acid, Mocetinostat, MS-275, Romidepsin, Panobinostat, and Chidamide lead to an increase in histone acetylation, which can disrupt the chromatin binding capacity of ZCWPW2. This disruption impedes ZCWPW2's ability to recognize specific histone marks, consequently diminishing its role in gene regulatory processes. Moreover, DNA methyltransferase inhibitors such as 5-Azacytidine, RG 108, 5-Aza-2′-Deoxycytidine, and SGI-1027 induce DNA hypomethylation, altering the methylation landscape that ZCWPW2 depends upon for its chromatin-associated functions.
The inhibition impact of these compounds on ZCWPW2 is rooted in their capacity to modulate the chromatin state, which is fundamental to ZCWPW2's activity. The DNA methyltransferase inhibitors, by causing DNA hypomethylation, challenge the epigenetic context within which ZCWPW2 operates, thereby diminishing its ability to interact with methylated DNA and histones effectively. This interference with ZCWPW2's recognition of epigenetic marks is crucial because it can lead to a cascade of downstream effects on gene expression regulation. The combined actions of these inhibitors, targeting key epigenetic modulators such as PKC, HDACs, and DNA methyltransferases, collectively contribute to the reduction of ZCWPW2's influence on chromatin dynamics and gene expression. Through such indirect yet specific mechanisms, these chemical compounds effectively impair the functional activity of ZCWPW2 in its native biological context, without directly altering its expression or translation.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
This compound is a potent and specific inhibitor of protein kinase C (PKC). ZCWPW2 has been implicated in histone modification processes which are in turn regulated by PKC signaling. Inhibition of PKC by Bisindolylmaleimide I would therefore lead to a diminished activity of ZCWPW2 by reducing the phosphorylation events that are critical for its function. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A is a histone deacetylase (HDAC) inhibitor. Given ZCWPW2’s role in chromatin modification, inhibiting HDAC activity could result in an increase in acetylation levels, thereby altering the chromatin state and diminishing ZCWPW2's ability to bind to its histone targets. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
This compound is a DNA methyltransferase inhibitor. It leads to hypomethylation of DNA, potentially altering the chromatin landscape and the binding capacity of ZCWPW2, which is involved in reading histone marks, thus diminishing its functional activity. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
Suberoylanilide Hydroxamic Acid is another HDAC inhibitor that would increase histone acetylation levels, potentially disrupting the interaction of ZCWPW2 with chromatin and diminishing its activity related to histone mark recognition. | ||||||
Mocetinostat | 726169-73-9 | sc-364539 sc-364539B sc-364539A | 5 mg 10 mg 50 mg | $214.00 $247.00 $1463.00 | 2 | |
Mocetinostat is a class I HDAC inhibitor, which would lead to changes in chromatin structure and function. This could diminish the ability of ZCWPW2 to interact with its histone targets. | ||||||
MS-275 | 209783-80-2 | sc-279455 sc-279455A sc-279455B | 1 mg 5 mg 25 mg | $24.00 $90.00 $212.00 | 24 | |
MS-275 is a selective HDAC inhibitor. By altering histone acetylation patterns, it would likely affect the chromatin binding landscape for ZCWPW2, thus diminishing its role in gene regulation. | ||||||
RG 108 | 48208-26-0 | sc-204235 sc-204235A | 10 mg 50 mg | $131.00 $515.00 | 2 | |
RG 108 inhibits DNA methyltransferases, leading to DNA demethylation. This alteration in DNA methylation status can impact ZCWPW2's chromatin binding and its associated functions. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $218.00 $322.00 $426.00 | 7 | |
As a DNA methyltransferase inhibitor, 5-Aza-2′-Deoxycytidine induces DNA hypomethylation which may disrupt the chromatin context and binding sites for ZCWPW2, reducing its functional activity. | ||||||
Romidepsin | 128517-07-7 | sc-364603 sc-364603A | 1 mg 5 mg | $218.00 $634.00 | 1 | |
Romidepsin is an HDAC inhibitor that could disrupt the chromatin interactions of ZCWPW2 by altering acetylation patterns, thereby diminishing its functional activity. | ||||||
Panobinostat | 404950-80-7 | sc-208148 | 10 mg | $200.00 | 9 | |
Panobinostat is a potent pan-HDAC inhibitor that would broadly affect histone acetylation and potentially reduce the chromatin-associated activity of ZCWPW2. | ||||||